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Background
The case reported involved the constellation of the
above signs and exceptional circumstances meant that
the right drug was not available at the time. Calcium
channel blockers were given for life-saving reasons.
However their value for that purpose is questionable
and may be dangerous.
Case report
Caucasian healthy man, 19 years old, was anesthetised
with propofol bolus, remifentanil perfusion and sevoflur-
ane maintenance. No muscle relaxants were used.
Tachycardia was treated at 30 minutes with proprano-
lol EV. Hypercapnia was evident at 50 minutes.
Hyperthermia was confirmed at 60 minutes and specific
attitudes were taken: sevoflurane was stopped and
replaced by propofol perfusion, O2 at 18 L/min, the
patient was cooled, diuresis promoted and dantrolene
was requested. At 70 minutes, muscle stiffness with ven-
tilatory difficulties (Paw>40 cmH2O, CO2ET>65 mmHg,
SpO2=82%), axillar temperature=40.5 ºC (0,2
oC/min) -
verapamil 5mg EV was given.
The arterial blood gases: pH=7.23, K+=6.2mEq/L.
Insulin and dextrose was used.
The dantrolene was delivered at 80min but the clinical
improvement delayed their administration to 120 min:
40 mg guided by K+ blood analysis. At 48 h the patient
had severe legs oedema and at 72 h blood CK=12,700
U/L. He was discharged at one week and had fully
recovered from renal and pereoneal nerve dysfunctions
in the following months.
This patient was treated in the maxillofacial depart-
ment, which is away from the main hospital unit. The
dantrolene unavailability is an issue of the anaesthesiolo-
gist’s responsibilities. We did not carry out that specific
checklist and were not aware of that situation. Portugal
does not have laboratories for definitive diagnosis of
malignant hyperthermia (MH) but the Larach clinical
grading scale to predict patients susceptibility give 70
points; in the range of 50 points or more classified as
almost certain. However, discussion of clinical signs and
its sequential identification might question the therapeutic
timing. If the therapy was implemented by the hypercap-
nia diagnosis, might the clinical evolution be different?
And would the drug arrive in time for a life-saving situa-
tion? Is there any clinical indication for rechecking the
local pharmacy?
We do not exclude the possibility that clinical improve-
ment might have been a consequence of previous therapeu-
tic measures; however, there was a temporal drug-effect.
The idea of using verapamil comes from experimental
laboratory research showing how extracellular calcium
affects the severity of MH and the pharmacologic applicabil-
ity. That decision was taken from the life-saving perspective
with available drugs knowing that a clinical-experimental
shortcut was followed with inherent danger.
Probably the clinical use of this drug, for such purpose,
is not repeatable, but its value in saving the patient’s life is
obvious.
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Conclusions
Research and patient care partnerships are an ongoing
process. There are various reasons why not all labora-
tory research translates into clinical applicability. How-
ever, mutual knowledge/information can be critical to
solving issues relevant to a patient’s life. The value of
calcium channel blockers when dantrolene was not
available for this patient with suspected MH is one such
successfully solved question.
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